FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037834629> ?p ?o ?g. }

• W3037834629 endingPage "11" @default.
• W3037834629 startingPage "1" @default.
• W3037834629 abstract "The term autologous fecal microbiota transplantation (a-FMT) refers herein to the use of one's feces during a healthy state for later use to restore gut microbial communities after perturbations. Generally, heterologous fecal microbiota transplantation (h-FMT), where feces from a ``healthy” donor is transplanted into a person with illness, has been used to treat infectious diseases such as recurrent Clostridioides difficile infection (CDI), with cure rates of up to 90%. In humans, due to limited response to medicines, h-FMT has become a hallmark intervention to treat CDI. Extrapolating the benefits from CDI, h-FMT has been attempted in various diseases, including inflammatory bowel disease (IBD), but clinical response has been variable and less effective (ranging between 24% and 50%). Differences in h-FMT clinical response could be because CDI is caused by a Clostridial infection, whereas IBD is a complex, microbiome-driven immunological inflammatory disorder that presents predominantly within the gut wall of genetically-susceptible hosts. FMT response variability could also be due to differences in microbiome composition between donors, recipients, and within individuals, which vary with diet, and environments, across regions. While donor selection has emerged as a key factor in FMT success, the use of heterologous donor stool still places the recipient at risk of exposure to infectious/pathogenic microorganisms. As an implementable solution, herein we review the available literature on a-FMT, and list some considerations on the benefits of a-FMT for IBD. The term autologous fecal microbiota transplantation (a-FMT) refers herein to the use of one's feces during a healthy state for later use to restore gut microbial communities after perturbations. Generally, heterologous fecal microbiota transplantation (h-FMT), where feces from a ``healthy” donor is transplanted into a person with illness, has been used to treat infectious diseases such as recurrent Clostridioides difficile infection (CDI), with cure rates of up to 90%. In humans, due to limited response to medicines, h-FMT has become a hallmark intervention to treat CDI. Extrapolating the benefits from CDI, h-FMT has been attempted in various diseases, including inflammatory bowel disease (IBD), but clinical response has been variable and less effective (ranging between 24% and 50%). Differences in h-FMT clinical response could be because CDI is caused by a Clostridial infection, whereas IBD is a complex, microbiome-driven immunological inflammatory disorder that presents predominantly within the gut wall of genetically-susceptible hosts. FMT response variability could also be due to differences in microbiome composition between donors, recipients, and within individuals, which vary with diet, and environments, across regions. While donor selection has emerged as a key factor in FMT success, the use of heterologous donor stool still places the recipient at risk of exposure to infectious/pathogenic microorganisms. As an implementable solution, herein we review the available literature on a-FMT, and list some considerations on the benefits of a-FMT for IBD." @default.
• W3037834629 created "2020-07-02" @default.
• W3037834629 creator A5000331805 @default.
• W3037834629 creator A5008150296 @default.
• W3037834629 creator A5025850410 @default.
• W3037834629 creator A5070485730 @default.
• W3037834629 creator A5087977422 @default.
• W3037834629 date "2020-12-01" @default.
• W3037834629 modified "2023-10-18" @default.
• W3037834629 title "Autologous fecal microbiota transplantation for the treatment of inflammatory bowel disease" @default.
• W3037834629 cites W1549833421 @default.
• W3037834629 cites W1994882377 @default.
• W3037834629 cites W2004736065 @default.
• W3037834629 cites W2023931031 @default.
• W3037834629 cites W2033649854 @default.
• W3037834629 cites W2056515449 @default.
• W3037834629 cites W2057411492 @default.
• W3037834629 cites W2074425838 @default.
• W3037834629 cites W2078599166 @default.
• W3037834629 cites W2078754045 @default.
• W3037834629 cites W2082509173 @default.
• W3037834629 cites W2087292184 @default.
• W3037834629 cites W2103966018 @default.
• W3037834629 cites W2125932918 @default.
• W3037834629 cites W2136552678 @default.
• W3037834629 cites W2148171446 @default.
• W3037834629 cites W2151566194 @default.
• W3037834629 cites W2157657209 @default.
• W3037834629 cites W2161590746 @default.
• W3037834629 cites W2166562121 @default.
• W3037834629 cites W2166691283 @default.
• W3037834629 cites W2288187473 @default.
• W3037834629 cites W2318207240 @default.
• W3037834629 cites W2344925875 @default.
• W3037834629 cites W2465534016 @default.
• W3037834629 cites W2506854111 @default.
• W3037834629 cites W2512654916 @default.
• W3037834629 cites W2512704070 @default.
• W3037834629 cites W2516509948 @default.
• W3037834629 cites W2534977774 @default.
• W3037834629 cites W2550586225 @default.
• W3037834629 cites W2567180129 @default.
• W3037834629 cites W2569074809 @default.
• W3037834629 cites W2576343201 @default.
• W3037834629 cites W2582073809 @default.
• W3037834629 cites W2586374101 @default.
• W3037834629 cites W2586719927 @default.
• W3037834629 cites W2588070196 @default.
• W3037834629 cites W2588997555 @default.
• W3037834629 cites W2594982553 @default.
• W3037834629 cites W2605872624 @default.
• W3037834629 cites W2610035002 @default.
• W3037834629 cites W2732891761 @default.
• W3037834629 cites W2735259022 @default.
• W3037834629 cites W2736759732 @default.
• W3037834629 cites W2749107782 @default.
• W3037834629 cites W2762290518 @default.
• W3037834629 cites W2766752206 @default.
• W3037834629 cites W2767131601 @default.
• W3037834629 cites W2785719692 @default.
• W3037834629 cites W2792147829 @default.
• W3037834629 cites W2792993260 @default.
• W3037834629 cites W2799975398 @default.
• W3037834629 cites W2800328740 @default.
• W3037834629 cites W2802670393 @default.
• W3037834629 cites W2802989498 @default.
• W3037834629 cites W2890289370 @default.
• W3037834629 cites W2890914486 @default.
• W3037834629 cites W2891057921 @default.
• W3037834629 cites W2893046185 @default.
• W3037834629 cites W2894598208 @default.
• W3037834629 cites W2896280219 @default.
• W3037834629 cites W2898527241 @default.
• W3037834629 cites W2900942517 @default.
• W3037834629 cites W2905076021 @default.
• W3037834629 cites W2910445001 @default.
• W3037834629 cites W2910898181 @default.
• W3037834629 cites W2913062716 @default.
• W3037834629 cites W2914196106 @default.
• W3037834629 cites W2922408081 @default.
• W3037834629 cites W2941740662 @default.
• W3037834629 cites W2945487772 @default.
• W3037834629 cites W2947584983 @default.
• W3037834629 cites W2954522570 @default.
• W3037834629 cites W2966229683 @default.
• W3037834629 cites W2981179503 @default.
• W3037834629 cites W2989757532 @default.
• W3037834629 cites W3001098195 @default.
• W3037834629 cites W3003244396 @default.
• W3037834629 cites W3009351593 @default.
• W3037834629 cites W3010428512 @default.
• W3037834629 cites W3010604545 @default.
• W3037834629 doi "https://doi.org/10.1016/j.trsl.2020.05.008" @default.
• W3037834629 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7308243" @default.
• W3037834629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32585148" @default.
• W3037834629 hasPublicationYear "2020" @default.
• W3037834629 type Work @default.
• W3037834629 sameAs 3037834629 @default.

• next